IMV Inc IMVIF

RE:Poster Conclusions

[alphaseeking001]

Thanks Texas.  I guess we'll find out the "some subjects" number at the end of the month hopefully... as long as it's effectiveness as a monotherapy in this difficult population is similar to what we've seen before in earlier DPX trials (contaminated with epacadostat)... we should be good.  Finger's crossed!

TexasTea20 wrote: In the event anyone hasnt seen this;


Conclusions

• DPX platform is a unique delivery system that allows the active uptake of peptides and presentation to nave T cells to generate antigen-specific T cell response.
• DPX-Survivac generates robust, functional, targeted, and sustained survivin-specific T cell response in ovarian cancer subjects in the maintenance setting as well as with recurrent disease. • DPX-Survivac induced activation of cytolytic T cell pathway is correlated with clinical response highlighting its unique mechanism of action.
• Enhanced number of unique survivin-specific T cell clones are detected in on-treatment tumor samples and the T cell infiltration on-treatment correlated with clinical responses.
• DPX-Survivac mechanism of action has been confirmed across multiple clinical trials and has shown to provide clinical benefit and long-term clinical response in some subjects with advanced recurrent ovarian cancer